Analysis of the clinical and molecular characteristics of a child with achondroplasia: A case report

Liu,Jingfang; Tang,Xulei; Cheng,Jianguo; Wang,Liting; Yang,Xiaomei; Wang,Yan

doi:10.3892/etm.2015.2324

Analysis of the clinical and molecular characteristics of a child with achondroplasia: A case report

Authors:
- Jingfang Liu
- Xulei Tang
- Jianguo Cheng
- Liting Wang
- Xiaomei Yang
- Yan Wang
View Affiliations

Affiliations: Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China
Published online on: March 2, 2015 https://doi.org/10.3892/etm.2015.2324
Pages: 1763-1767

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Achondroplasia (ACH) is a hereditary dwarfism caused by the disturbed proliferation and differentiation of growth plate chondrocytes, followed by impaired endochondral bone growth. ACH is caused by mutations in the gene encoding the transmembrane receptor, fibroblast growth factor receptor 3 (FGFR3). In total, >90% of patients with ACH have a G1138A mutation in the transmembrane domain of the FGFR3 gene. Patients with ACH usually have no growth hormone (GH) deficiency. The current study presents the case of a four‑year‑old male with clinical manifestations suggestive of ACH, including a large head, prominent forehead, short upper arms and legs, and short hands with fingers assuming a trident position. The patient showed normal responses to GH provocation tests with L‑dopa (peak GH concentration, 42.38 ng/ml) and insulin (peak GH concentration, 23.29 ng/ml during hypoglycemia), but a blunted response to a GH provocation test with arginine (peak GH concentration, 7.31 ng/ml). Furthermore, the GH concentration during exercise was low (4.8 ng/ml). Magnetic resonance imaging revealed a decreased pituitary volume. Thyroid function tests and the levels of sex hormones (follicle stimulating hormone, luteinizing hormone, estradiol, prolactin and progesterone), cortisol and adrenocorticotropic hormone were normal. A heterozygous G1138A mutation within the FGFR3 gene was detected, confirming the diagnosis of ACH. Thus, recombinant human GH therapy (0.1 IU/kg/day) was initiated. At the six‑month follow‑up, the height, arm span‑to‑height ratio and lower limb length‑to‑height ratio of the patient had increased, while the head circumference had decreased. The present results corroborate the finding that the G1138A mutation within FGFR3 is the most common ACH‑causing mutation in different populations. GH may be beneficial in the treatment of short stature in ACH patients with subnormal GH secretion.

View Figures

View References

1	Placone J and Hristova K: Direct assessment of the effect of the Gly380Arg achondroplasia mutation on FGFR3 dimerization using quantitative imaging FRET. PLoS One. 7:e466782012. View Article : Google Scholar : PubMed/NCBI
2	Orioli IM, Castilla EE and Barbosa-Neto JG: The birth prevalence rates for the skeletal dysplasias. J Med Genet. 23:328–332. 1986. View Article : Google Scholar : PubMed/NCBI
3	Horton WA, Hall JG and Hecht JT: Achondroplasia. Lancet. 370:162–172. 2007. View Article : Google Scholar : PubMed/NCBI
4	Su N, Xu X, Li C, et al: Generation of Fgfr3 conditional knockout mice. Int J Biol Sci. 6:327–332. 2010. View Article : Google Scholar : PubMed/NCBI
5	Shiang R, Thompson LM, Zhu YZ, et al: Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 78:335–342. 1994. View Article : Google Scholar : PubMed/NCBI
6	Rousseau F, Bonaventure J, Legeai-Mallet L, et al: Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature. 371:252–254. 1994. View Article : Google Scholar : PubMed/NCBI
7	Li YQ, Li QL and Zhang MH: Comparison of diagnostic value of growth hormone exercise test and growth hormone provocative test on growth hormone deficiency. J Appl Clin Pediatr. 24:601–602. 2009.
8	Francomano CA, Ortiz de Luna RI, Hefferon TW, et al: Localization of the achondroplasia gene to the distal 2. 5Mb of human chromosome 4p. Hum Mol Genet. 3:787–792. 1994. View Article : Google Scholar : PubMed/NCBI
9	He X, Xie F and Ren ZR: Rapid detection of G1138A and G1138C mutations of the FGFR3 gene in patients with achondroplasia using high-resolution melting analysis. Genet Test Mol Biomarkers. 16:297–301. 2012. View Article : Google Scholar : PubMed/NCBI
10	Pehlivan S, Ozkinay F, Okutman O, et al: Achondroplasia in Turkey is defined by recurrent G380R mutation of the FGFR3 gene. Turk J Pediatr. 45:99–101. 2003.PubMed/NCBI
11	Cui Y, Zhao H, Liu Z, Liu C, Luan J, Zhou X and Han J: A systematic review of genetic skeletal disorders reported in Chinese biomedical journals between 1978 and 2012. Orphanet J Rare Dis. 7:552012. View Article : Google Scholar : PubMed/NCBI
12	Superti-Furga A, Eich G, Bucher HU, Wisser J, Giedion A, Gitzelmann R and Steinmann B: A glycine 375-to-cysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a new born with achondroplasia. Eur J Pediatr. 154:215–219. 1995. View Article : Google Scholar : PubMed/NCBI
13	Prinos P, Kilpatrick MW and Tsipouras P: A novel G346E mutation in achondroplasia. Pediatr Res. 37:151A1994.
14	Zhang SR, Zhou XQ, Ren X, et al: Ser217Cys mutation in the Ig II domain of FGFR3 in a Chinese family with autosomal dominant achondroplasia. Chin Med J (Engl). 120:1017–1019. 2007.PubMed/NCBI
15	Coutts JC and Gallagher JT: Receptors for fibroblast growth factors. Immunol Cell Biol. 73:584–589. 1995. View Article : Google Scholar : PubMed/NCBI
16	Mohammadi M, Dikic I, Sorokin A, Burgess WH, Jaye M and Schlessinger J: Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol Cell Biol. 16:977–989. 1996.PubMed/NCBI
17	Webster MK and Donoghue DJ: Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J. 15:520–527. 1996.PubMed/NCBI
18	Naski MC, Wang Q, Xu J and Ornitz DM: Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet. 13:233–237. 1996. View Article : Google Scholar : PubMed/NCBI
19	Matsushita T, Wilcox WR, Chan YY, et al: The FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway. Hum Mol Genet. 18:227–240. 2009. View Article : Google Scholar : PubMed/NCBI
20	Tanaka N, Katsumata N, Horikawa R and Tanaka T: The comparison of the effects of short-term growth hormone treatment in patients with achondroplasia and with hypochondroplasia. Endocr J. 50:69–75. 2003. View Article : Google Scholar : PubMed/NCBI
21	Tanaka H, Kubo T, Yamate T, Ono T, Kanzaki S and Seino Y: Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function, and genotype. Eur J Endocrinol. 138:275–280. 1998. View Article : Google Scholar : PubMed/NCBI
22	Ramaswami U, Rumsby G, Spoudeas HA, Hindmarsh PC and Brook CG: Treatment of achondroplasia with growth hormone: six years of experience. Pediatr Res. 46:435–439. 1999. View Article : Google Scholar : PubMed/NCBI
23	Yamate T, Kanzaki S, Tanaka H, et al: Growth hormone (GH) treatment in achondroplasia. J Pediatr Endocrinol. 6:45–52. 1993. View Article : Google Scholar : PubMed/NCBI
24	Escamilla RF, Hutchings JJ, Li CH and Forsham P: Achondroplastic dwarfism Effects of treatment with human growth hormone. Calif Med. 105:104–110. 1996.
25	Seino Y, Yamanaka Y, Shinohara M, et al: Growth hormone therapy in achondroplasia. Horm Res. 53:53–56. 2000. View Article : Google Scholar : PubMed/NCBI
26	Wilkin DJ, Szabo JK, Cameron R, et al: Mutations in fibroblast growth factor receptor 3 in sporadic cases of achondroplasia occur exclusively on the paternally derived chromosome. Am J Hum Genet. 63:711–716. 1998. View Article : Google Scholar : PubMed/NCBI